MAPT and early-onset autosomal dominant Alzheimer disease: Collectively, the evidence indicates that MPs and NPs act as accelerators of Alzheimer’s disease pathology, enhancing Aβ and tau aggregation, compromising microglial and BBB function, and causing systemic perturbations that drive disease progression.